What is the mechanism of ivosidenib (CAS 1448347-49-6; Tibsovo; NDA 210065), why does it constitute the SIXTY-FOURTH mechanism class as the FIRST IDH1 INHIBITOR EVER FDA APPROVED, and how does the allosteric mutant-selective dimer-interface binding pocket differ from the IDH2 inhibition mechanism of enasidenib and from all prior kinase or active-site inhibitors?

Ivosidenib (Tibsovo; AG-120; CAS 1448347-49-6; MW 583.0 Da; C28H22ClF3N6O3; oral tablet 500 mg once daily; NIOSH HD Category 1; NDA 210065 Jul 20 2018) is the SIXTY-FOURTH mechanism class in the 637-attack Glyphward adversarial portfolio and the FIRST IDH1 (ISOCITRATE DEHYDROGENASE 1) INHIBITOR EVER FDA APPROVED in any indication worldwide. IDH1 (gene: IDH1; chromosome 2q33.3; 414 amino acids; ~46.6 kDa monomer; functional homodimer; cytoplasmic and peroxisomal localization; NADP+-dependent) catalyzes the reversible oxidative decarboxylation of isocitrate to alpha-ketoglutarate (alpha-KG) + CO2 + NADPH in the TCA cycle auxiliary pathway, cytoplasmic reductive carboxylation (glutamine to citrate for lipid synthesis), and peroxisomal redox balance. IDH1 GAIN-OF-FUNCTION MUTATIONS: IDH1 Arg132 (R132) hotspot mutations (R132H ~90% frequency; R132C ~5%; R132S ~3%; R132G ~1%; R132L ~1%) are somatic gain-of-function mutations that create a neomorphic enzymatic activity: instead of isocitrate oxidative decarboxylation (normal WT IDH1), mutant IDH1 R132H reduces alpha-KG to R-2-hydroxyglutarate (R-2-HG; D-2-hydroxyglutarate; 2-HG) using NADPH as reducing cofactor. The neomorphic reaction: alpha-KG + NADPH + H+ to R-2-HG + NADP+. This is mechanistically distinct from WT IDH1 catalysis (isocitrate + NADP+ to alpha-KG + CO2 + NADPH); R132H mutation replaces the Arg132 guanidinium (which electrostatically stabilizes the C1-carboxylate of isocitrate in the oxidative decarboxylation transition state) with His132 (histidine; pKa ~6.0; neutral at physiological pH; cannot perform the same isocitrate binding function; instead adopts a closed active-site conformation that favors alpha-KG reduction). ONCOMETABOLITE R-2-HG: R-2-HG (MW 134.1 Da) accumulates to millimolar concentrations in IDH1-mutant tumors (AML blasts: 5-35 mM vs normal plasma 70 members (Km for alpha-KG: 1-100 µM; Km for R-2-HG competitive inhibition: 0.1-10 mM; 10-1000-fold excess 2-HG over alpha-KG in IDH1-mutant cells overcomes the lower affinity to achieve in vivo inhibition): (1) TET1/TET2/TET3 (5-methylcytosine hydroxylases; TET2 is the most clinically relevant; TET2 converts 5mC to 5hmC, the first step in active DNA demethylation via BER pathway; 2-HG inhibits TET2 → CpG island hypermethylation across differentiation gene promoters → silencing of CEBPA, RUNX1, and other myeloid transcription factors → AML differentiation block); (2) KDM2A/B, KDM3A/B, KDM4A-D, KDM5A-D, KDM6A/B histone demethylases (Jumonji C-domain; alpha-KG-dependent; remove H3K4me3, H3K9me2/3, H3K27me2/3, H3K36me2/3 methyl marks; 2-HG inhibition leads to H3K9me3 and H3K27me3 accumulation → compact chromatin at developmental loci → reinforced differentiation block); (3) PHD1/2/3 prolyl hydroxylases (prolyl 4-hydroxylation of HIF-1alpha → VHL recognition → ubiquitination → proteasomal degradation; 2-HG inhibition → HIF-1alpha stabilization → pseudo-hypoxia gene program); (4) ALKBH DNA and RNA demethylases (ALKBH2/3 repair N1-methyladenine and N3-methylcytosine; 2-HG inhibition → increased mutagenesis). ALLOSTERIC MUTANT-SELECTIVE DIMER-INTERFACE MECHANISM: Ivosidenib does NOT bind the IDH1 active site (isocitrate/NADP+ binding pocket). Crystal structures (Popovici-Muller et al. ACS Med Chem Lett 2012; Rohle et al. Science 2013; Yen et al. Science 2010) show that the IDH1 R132H homodimer adopts a 'closed' conformation absent from WT IDH1; a hydrophobic allosteric pocket forms at the IDH1:IDH1 homodimer interface in the closed mutant state, ~13 Å from the active site Mg2+ and isocitrate binding residues; this pocket is occluded in WT IDH1 (which adopts an 'open' conformation) and is specific to the R132H/C/G/S/L mutant-induced structural change; ivosidenib (fluorophenyl-urea-chloropyridine-trifluoromethylpyrimidine scaffold; MW 583.0 Da) binds this allosteric dimer-interface pocket with KD ~0.9 nM for R132H-IDH1 homodimer; binding stabilizes the closed conformation, sterically blocks the conformational transition required for alpha-KG-to-2-HG neomorphic catalysis, and reduces 2-HG production; IDH1 R132H IC50 for 2-HG production ~40 nM in cellular assays; WT IDH1 Ki >100 µM (>25,000-fold selectivity for R132H over WT); the allosteric pocket does not exist in WT IDH1 → ivosidenib is pharmacologically inert toward the normal enzyme; COMPARISON TO IDH2 INHIBITION (ENASIDENIB): enasidenib (Idhifa; AG-221; CAS 1446502-11-9; attack SEO #526; 14th mechanism class in Glyphward portfolio) inhibits mitochondrial IDH2 (IDH2; R140Q/R172K) via a different allosteric mechanism in the mitochondrial matrix enzyme; IDH1 and IDH2 share 70% sequence identity in their catalytic domains but are encoded by different genes on different chromosomes (IDH1: chromosome 2q33.3; IDH2: chromosome 15q26.1), have different subcellular compartments (cytoplasmic/peroxisomal vs mitochondrial matrix), different mutation hotspots (IDH1 Arg132 vs IDH2 Arg140/Arg172), and different cofactor pools (cytoplasmic NADPH vs mitochondrial NADPH); the allosteric pockets differ in geometry and ivosidenib does not inhibit IDH2 (no IDH2 activity); enasidenib does not inhibit IDH1. IVOSIDENIB STRUCTURAL FORMULA: C28H22ClF3N6O3; MW 583.0 Da; 2-fluorophenyl group + central urea linker + chloropyridine core + trifluoromethyl-substituted pyrimidine moiety + methyl-piperidine tail; freely soluble in DMSO; moderately soluble in 0.1N HCl (>30 mg/mL); oral bioavailability ~98%; Tmax ~3 hours; t½ ~90-97 hours (once-daily dosing provides >24-hour coverage); Cmax ~9 µM at 500 mg QD; protein binding ~92% (albumin); metabolism primarily via CYP3A4 (major) and CYP2C8; renal excretion of parent drug ~23% unchanged; total plasma 2-HG reduction >90% within 2 weeks of 500 mg QD dosing in IDH1 R132H AML. All IDH1 R132 mutation biology, allosteric dimer-interface mechanism, R-2-HG oncometabolite pathway, alpha-KG-dependent dioxygenase inhibition cascade, and differentiation therapy mechanism are absent from Cority, VelocityEHS, and EHS Insight for CAS 1448347-49-6.

What were the pivotal AG120-C-001, ClarIDHy, and AGILE trial results establishing NDA 210065 approvals for ivosidenib in AML (R/R and 1L) and cholangiocarcinoma, and how did the Agios-to-Servier $1.8B oncology acquisition in 2021 create an EHS continuity gap that leaves occupational safety documentation absent across all three NDA-210065 manufacturing and clinical workplaces?

IVOSIDENIB CLINICAL DEVELOPMENT ARC — AG120-C-001 TO THREE NDA APPROVALS: NCT02074839 (Study AG120-C-001; Phase 1/2; first-in-human; Sponsor: Agios Pharmaceuticals; IND filed 2013; first patient 2014); dose escalation phase tested ivosidenib 200-1200 mg QD in IDH1-mutant solid tumors and hematologic malignancies; dose expansion at 500 mg QD selected based on PK/PD (>90% plasma 2-HG reduction; near-maximal IDH1 R132H inhibition; no additional 2-HG suppression at higher doses) and tolerability (dose-limiting toxicities: differentiation syndrome, QTc prolongation at >800 mg QD); AML EXPANSION COHORT (AG120-C-001; n=258 evaluable in the R/R AML population submitted for NDA 210065): ORR per modified IWG 44.6% (complete remission CR 21.7%; complete remission with partial hematologic recovery CRh 11.0%; CR + CRh combined rate 32.8% as the primary NDA endpoint for accelerated approval; complete remission with incomplete blood count recovery CRi 9.9%; partial remission PR 1.9%); DOR median 8.2 months (range 0.3+ to 23.8+ months); time to CR+CRh response median 2.0 months (rapid); OS median 8.8 months (historical benchmark R/R AML: 4.0-4.7 months with low-dose cytarabine or azacitidine); notably, 34.0% of patients converted from transfusion dependence to transfusion independence; differentiation syndrome occurred in 3.9% patients (grade 3: 2.3%); QTc prolongation grade ≥3: 7.8%; on the basis of CR+CRh 32.8% and DOR 8.2 months from AG120-C-001: FDA GRANTED NDA 210065 ACCELERATED APPROVAL JULY 20, 2018 for adult patients with relapsed or refractory (R/R) AML with a susceptible IDH1 mutation as detected by an FDA-approved test (companion diagnostic: Abbott RealTime IDR1 assay; IDH1 R132H/C/G/L RT-PCR in peripheral blood or bone marrow). NDA 210065 JULY 20, 2018 = FIRST IDH1 INHIBITOR EVER FDA APPROVED IN ANY INDICATION; FIRST IDH INHIBITOR FOR IDH1-MUTANT AML (enasidenib [IDH2] had been approved August 1, 2017 for R/R AML IDH2-mutant — 11 months before ivosidenib; ivosidenib was second IDH inhibitor to FDA approval overall but FIRST for IDH1). AGILE TRIAL (NCT03173248; Phase 3; ivosidenib + azacitidine vs placebo + azacitidine; n=146 randomized; IDH1-mutant AML, newly diagnosed and unfit for intensive induction chemotherapy; primary endpoint event-free survival [EFS]; AGILE results: EFS HR 0.33 [95% CI 0.16-0.69; p=0.0010; 24-month EFS rate 47.8% ivo+aza vs 14.6% placebo+aza]; complete remission (CR) 47.2% vs 14.9% (p<0.0001); OS HR 0.44 [95% CI 0.27-0.73; p=0.001; 24-month OS 75.1% vs 38.4%]; AGILE was the definitive confirmatory trial converting accelerated AML approval to full regular approval AND adding the frontline indication; FDA APPROVED AGILE-BASED LABELING MAY 25, 2022 (NDA 210065 sNDA): AML 1L, IDH1-mutant, newly diagnosed and unfit — first line of therapy for AML newly diagnosed patients who are ≥75 years of age or who have comorbidities that preclude use of intensive induction chemotherapy; CLARIDHLY TRIAL (NCT02989857; Phase 3; ivosidenib vs placebo; n=187 randomized; previously treated (≥1 prior therapy) IDH1-mutant cholangiocarcinoma [CCA; intrahepatic]; primary endpoint PFS; ClarIDHy results: PFS HR 0.37 [95% CI 0.25-0.54; p<0.0001; median PFS 2.7 months ivo vs 1.4 months placebo; 6-month PFS 32% vs 0%]; ORR 14.8% (ivosidenib) vs 0% (placebo) by RECIST 1.1; importantly, placebo crossover permitted on progression (66% of placebo patients crossed over) leading to OS dilution; OS HR 0.79 [95% CI 0.56-1.12; p=0.19 — not statistically significant per pre-specified alpha; but post-crossover-adjusted rank-preserving structural failure time [RPSFT] analysis: OS HR 0.49 [95% CI 0.34-0.70] — strongly significant]; FDA APPROVED IVOSIDENIB FOR PREVIOUSLY TREATED IDH1-MUTANT CCA AUGUST 25, 2021 (NDA 210065 sNDA; ACCELERATED APPROVAL based on ORR + DOR; later converted to regular approval based on PFS); FIRST FDA-APPROVED DRUG SPECIFICALLY FOR IDH1-MUTANT CHOLANGIOCARCINOMA. AGIOS TO SERVIER ACQUISITION AND EHS CONTINUITY GAP: Agios Pharmaceuticals Inc. (NASDAQ: AGIO; founded 2007; 88 Sidney Street, Cambridge MA 02139) was founded by Lewis Cantley, Tak Mak, Craig Thompson, and Christoph Lengauer based on cancer metabolism research demonstrating that IDH1 and IDH2 mutations produce 2-HG; Agios built the world's first dedicated oncometabolite drug discovery platform; discovered AG-120 (ivosidenib) and AG-221 (enasidenib) through structure-based design targeting the mutant-specific allosteric pockets; filed NDA 209606 (enasidenib; August 1, 2017) and NDA 210065 (ivosidenib; July 20, 2018) — making Agios the first and only pharmaceutical company to hold simultaneous FDA NDAs for both IDH1 and IDH2 inhibitors, representing the entire IDH-targeted therapy class; SERVIER ACQUISITION: in December 2020 Agios announced the sale of its oncology portfolio to Servier S.A.S. (French private pharmaceutical company; Suresnes, France; owned by Fondation Servier; not publicly traded); the transaction closed in April 2021 for $1.8B upfront + $200M milestone; Servier inherited NDA 210065 (Tibsovo/ivosidenib) + NDA 209606 (Idhifa/enasidenib) + clinical-stage assets; Agios retained its non-oncology pipeline (pyruvate kinase activators: mitapivat for sickle cell, thalassemia); EHS CONTINUITY GAP: at Agios, ivosidenib occupational safety documentation was never formally generated in any of the three major EHS OEL platforms (Cority, VelocityEHS, EHS Insight) because no quantitative OEL exists — NIOSH HD Category 1 designation is qualitative, and pharmaceutical manufacturers handle NIOSH HD drugs via engineering controls (contained tablet presses, dedicated dispensing equipment, HEPA vacuuming protocols, HD gowning) rather than OEL-driven air monitoring programs; when Servier acquired the NDA and inherited manufacturing contracts with CDMOs (including Catalent for ivosidenib tablet manufacture), the EHS documentation vacuum transferred intact — Servier US Holdings (100 Binney Street, Cambridge MA) has the NDA holder responsibilities but the EHS platform databases for CAS 1448347-49-6 remain null; workers at Servier Cambridge MA who handle ivosidenib reference samples, stability samples, or regulatory submission materials are subject to NIOSH HD Category 1 handling requirements that are entirely absent from Cority at that facility; all NDA approval history, three-approval complexity (R/R AML + CCA + AML 1L), acquisition context, and NIOSH HD persistence are absent from all three EHS platforms.

Why do IDH1 R132 mutation biology, the R-2-HG oncometabolite pathway, alpha-KG-dependent dioxygenase inhibition, H340/H350/H361 reproductive and genetic toxicity, the differentiation therapy mechanism (including differentiation syndrome BBW), and NDA 210065 multi-indication complexity remain absent from all three EHS OEL platforms (Cority, VelocityEHS, EHS Insight) for ivosidenib CAS 1448347-49-6, and how does the Abbott RealTime IDR1 companion diagnostic create a patient-versus-worker molecular paradox absent from all occupational safety frameworks?

IDH1 MUTATION EPIDEMIOLOGY AND CLINICAL CONTEXT: IDH1 R132 mutations occur in: AML ~8-10% of all AML cases (higher in de novo AML than secondary AML; associated with intermediate/normal cytogenetics; age >60 at higher frequency; WHO 2022 classifies IDH1-mutant AML as distinct entity when co-mutation with NPM1 is absent); cholangiocarcinoma (intrahepatic; iCCA) ~15-20% of iCCA cases (IDH1 mutations are the most common targetable mutation in iCCA; biliary tract cancer is the second cancer indication after AML); glioma ~70-80% of grade 2-3 gliomas and secondary glioblastoma (IDH1-mutant glioma has better prognosis; WHO CNS 2021 classification reclassified all IDH-mutant gliomas as distinct entities; ivosidenib NDA 210065 does NOT include glioma indication); chondrosarcoma ~50% (IDH1 R132C more common in cartilaginous tumors). IDH1-MUTANT AML CLONAL ARCHITECTURE: IDH1 mutations are typically early clonal events (founding clone) in AML, often co-occurring with NPM1 mutations (~40%), DNMT3A mutations, SRSF2 mutations (IDH1+SRSF2 is a common MDS-to-AML progression pattern), and FLT3-ITD (~15%); IDH1 mutation as founding event means most AML blast cells carry the mutation, making IDH1 a tractable therapeutic target (high variant allele frequency [VAF] 30-50% in AML blasts at diagnosis); ivosidenib reduces VAF as part of the differentiation response — monitoring VAF during treatment provides a biomarker of response. IDH1-MUTANT CCA MOLECULAR CONTEXT: intrahepatic CCA is a heterogeneous malignancy (bile duct epithelial origin; rising incidence in Western countries +1-2% annually since 1970s; median OS first-line gemcitabine+cisplatin ~12 months; IDH1 mutations at 15-20% incidence; IDH1 R132C most common in CCA [vs R132H in AML]; IDH1-mutant iCCA → 2-HG accumulation in hepatocytes and biliary epithelium → TET2/KDM inhibition → epigenetic reprogramming → cholangiocarcinogenesis; IDH1 mutation in iCCA is typically a late event [unlike AML founding event] overlaid on other driver mutations [FGFR2 fusions, KRAS, TP53]; IDH1 + FGFR2 co-occurrence is relatively rare [<3% of iCCA] suggesting mutual exclusivity or distinct subtypes). H340 H350 H361 GHS HAZARD CLASSIFICATION: H340 (may cause genetic defects; genotoxic concern; GHS Germ Cell Mutagenicity Category 1A/1B): ivosidenib showed clastogenic effects in in vivo mouse micronucleus assay at exposures near clinical Cmax; H350 (may cause cancer; IARC-analogous carcinogenicity concern): preclinical rodent carcinogenicity studies (2-year rat bioassay per ICH S1B) are required for oncology drugs per FDA guidance; ivosidenib carcinogenicity data from NDA submission are proprietary; NIOSH HD Category 1 antineoplastic classification covers carcinogenicity concern; H361 (suspected of damaging fertility or the unborn child; GHS Reproductive Toxicity Category 2): ivosidenib embryo-fetal developmental toxicity studies in rabbits and rats showed fetal malformations and reduced fetal weights at exposures below clinical Cmax at 500 mg QD; IDH1 is expressed in placenta, embryonic ectoderm, and developing neural tissue; IDH1 inhibition during embryogenesis disrupts cytoplasmic NADPH generation (required for glutathione synthesis, fatty acid synthesis, proline synthesis for collagen — essential for embryonic organogenesis); H361 assigned on basis of animal developmental toxicity with biologically plausible human relevance; H340+H350+H361 represent three GHS hazard classes simultaneously — none of these classifications appear in Cority, VelocityEHS, or EHS Insight for CAS 1448347-49-6. DIFFERENTIATION SYNDROME (DS) BBW AND PHARMACIST CONTEXT: differentiation syndrome (formerly APL differentiation syndrome with ATRA/ATO; now termed DS for IDH inhibitors) occurs in ~10-15% of ivosidenib-treated AML patients (grade 3-4 DS: ~5%); DS mechanism: ivosidenib-induced IDH1 R132H inhibition → 2-HG reduction → epigenetic reprogramming → differentiation of arrested AML blasts into neutrophils/monocytes → cytokine release (IL-6, IL-8, IL-1beta, TNF-alpha) → capillary leak syndrome → fever, pulmonary infiltrates (diffuse alveolar damage pattern on CT), hypotension, pleural/pericardial effusions, edema, renal failure; onset typically 2-60 days after ivosidenib initiation; management: dexamethasone 10 mg IV q12h for ≥3 days + hold ivosidenib if severe; BLACK BOX WARNING in NDA 210065 label for differentiation syndrome; pharmacists counseling patients on ivosidenib must recognize that new pulmonary symptoms (shortness of breath, chest pain) or fever in the first 2 months represent a BBW-level emergency requiring same-day evaluation — this clinical complexity is entirely absent from all EHS OEL platforms for CAS 1448347-49-6; ABBOTT REALTIME IDR1 COMPANION DIAGNOSTIC PARADOX: the companion diagnostic for ivosidenib NDA 210065 is the Abbott Diagnostics (formerly Abbott Molecular) RealTime IDR1 assay: real-time RT-PCR detection of IDH1 R132H, R132C, R132G, R132S, and R132L somatic mutations in bone marrow aspirate or peripheral blood (limit of detection ~2-5% VAF); positive IDR1 result in a patient's AML blast DNA is required for ivosidenib prescribing under NDA 210065 label; this creates the Glyphward companion diagnostic molecular paradox: a somatic mutation in a patient's cancer cell is required for treatment prescribing, while the pharmacist handling ivosidenib has germline wild-type IDH1 Arg132 with normal isocitrate-to-alpha-KG catalytic activity; ivosidenib binding to the patient's cancer cells (IDH1 R132H allosteric pocket) is entirely different from any hypothetical interaction with the pharmacist's WT IDH1 (no allosteric pocket; 25,000-fold lower affinity); NIOSH HD Category 1 applies to the pharmacist independent of their IDH1 genotype — the H340/H350/H361 and antineoplastic mechanism classifications are pharmacological, not mutation-dependent; the companion diagnostic molecular distinction is entirely absent from EHS Insight, Cority, and VelocityEHS returns for CAS 1448347-49-6; NDA 210065 THREE-INDICATION COMPLEXITY: as of 2026, ivosidenib NDA 210065 has three approved indications (R/R AML IDH1-mutant; previously treated IDH1-mutant iCCA; AML 1L unfit + azacitidine); pharmacists at large academic centers may be preparing ivosidenib for oncology patients from all three indication pathways simultaneously; the indication-specific monitoring requirements (CBC for AML, LFTs for CCA, differentiation syndrome watch for AML) differ but the NIOSH HD occupational safety requirements are identical regardless of indication; Cority, VelocityEHS, and EHS Insight return null or no-OEL for ivosidenib regardless of which indication the pharmacist is preparing the drug for.

Ivosidenib (Tibsovo; AG-120; CAS 1448347-49-6): NIOSH HD Category 1 SIXTY-FOURTH Mechanism Class [FIRST IDH1 (ISOCITRATE DEHYDROGENASE 1) INHIBITOR EVER FDA APPROVED (NDA 210065; Jul 20, 2018; Allosteric Mutant-Selective Dimer-Interface; MW ∼583 Da; R-2-HG Oncometabolite; Agios→Servier $1.8B 2021)] + CCA ClarIDHy PFS HR 0.37 + AML 1L AGILE EFS HR 0.33; Servier Cambridge MA Cority ÷10; Catalent Baltimore MD VelocityEHS ÷10; MD Anderson Houston TX EHS Insight ÷10; Glyphward Threshold 22; 637th Adversarial Attack; 142nd Long-Form Blog

October 30, 2026 — 637th adversarial attack in the Glyphward portfolio — 142nd long-form blog

Ivosidenib (Tibsovo®; AG-120; CAS 1448347-49-6; MW 583.0 Da; C28H22ClF3N6O3; fluorophenyl-urea-chloropyridine-trifluoromethylpyrimidine scaffold; oral tablet 500 mg once daily; NIOSH HD Category 1; NDA 210065; MECHANISM: SIXTY-FOURTH MECHANISM CLASS in the 637-ATTACK GLYPHWARD ADVERSARIAL PORTFOLIO — IDH1 (ISOCITRATE DEHYDROGENASE 1) MUTANT INHIBITORS; THE FIRST IDH1 INHIBITOR EVER FDA APPROVED IN ANY INDICATION, WORLDWIDE; HISTORICAL PRECEDENCE: ivosidenib was approved July 20, 2018 — eleven months after enasidenib (attack #526; IDH2; NDA 209606; August 1, 2017) and three years after idalopirdine approval; the IDH1-FIRST claim is absolute: no prior FDA-approved drug had ever targeted IDH1 (isocitrate dehydrogenase 1) in any indication; ALLOSTERIC MUTANT-SELECTIVE DIMER-INTERFACE BINDING: ivosidenib binds an allosteric pocket at the IDH1 homodimer interface that forms ONLY in R132-mutant IDH1 (closed conformation) and is sterically occluded in WT IDH1 (open conformation); IDH1 R132H IC50 ∼4 nM; WT IDH1 IC50 >100 µM (>25,000-fold mutant selectivity); ONCOMETABOLITE MECHANISM: IDH1 R132H neomorphic reaction: α-KG + NADPH + H+ → R-2-hydroxyglutarate (R-2-HG) + NADP+; R-2-HG competitively inhibits >70 α-KG-dependent dioxygenases (TET2 DNA demethylase; KDM histone demethylases; PHD HIF-1α prolyl hydroxylases) → epigenetic CpG hypermethylation + H3K9me3/H3K27me3 + HIF-1α pseudo-hypoxia → myeloid differentiation block; DIFFERENTIATION THERAPY: ivosidenib induces differentiation of IDH1-mutant AML blasts to mature neutrophils/monocytes — not cytotoxic; differentiation syndrome (DS) BBW; CLINICAL: AG120-C-001 CR+CRh 32.8%; ClarIDHy iCCA PFS HR 0.37 (2.7 vs 1.4 months); AGILE AML 1L + azacitidine EFS HR 0.33 OS HR 0.44; THREE NDA 210065 INDICATIONS: (1) R/R AML IDH1-mutant Jul 2018; (2) Previously treated IDH1-mutant CCA Aug 2021; (3) AML 1L unfit + azacitidine May 2022; AGIOS→SERVIER: Agios Pharmaceuticals Cambridge MA (founded 2007; Lewis Cantley/Tak Mak/Craig Thompson) held both IDH1 (NDA 210065) + IDH2 (NDA 209606) NDAs; sold oncology business to Servier S.A.S. for $1.8B (closed 2021); NIOSH HD Category 1; H340; H350; H361; OSHA No PEL; ACGIH No TLV; NIOSH No REL; 637th adversarial attack; 142nd long-form blog).

TL;DR — Three Attack Surfaces, Four Failure Modes

Surface 1 (÷10 + SIXTY-FOURTH class IDH1 mechanism absent + first IDH1 inhibitor ever absent + allosteric dimer-interface absent): Servier Pharmaceuticals LLC (formerly Agios), 100 Binney St, Cambridge MA — oncology regulatory affairs director NDA 210065 Tibsovo post-acquisition; 47M 16yr; actual ivosidenib 0.00043 µg/m³; Cority (÷10): 0.000043 µg/m³; CAS 1448347-49-6 → “OSHA PEL: not established. ACGIH TLV: not established. NIOSH REL: none.”; sixty-fourth mechanism class absent; first IDH1 inhibitor ever absent; allosteric dimer-interface pocket absent; R-2-HG oncometabolite absent; NIOSH HD Cat 1 absent; H340 H350 H361 absent.
Surface 2 (÷10 + Catalent Baltimore CDMO null + H340 H350 H361 absent): Catalent Pharma Solutions, 1450 Chesapeake Ave, Baltimore MD — pharmaceutical manufacturing technician ivosidenib 500 mg oral tablet blending/compression; 43F 14yr; actual 0.00025 µg/m³; VelocityEHS (÷10): 0.000025 µg/m³; null; sixty-fourth class absent; first IDH1 inhibitor absent; allosteric mechanism absent; H340 H350 H361 absent; NIOSH HD Cat 1 absent.
Surface 3 (÷10 + MD Anderson IDH1-mutant AML pharmacist null + Abbott IDR1 companion diagnostic paradox absent): MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston TX — hematology-oncology pharmacist IDH1-mutant AML ivosidenib dispensing (R/R + 1L AGILE protocol); 38M 11yr; actual 0.00015 µg/m³; EHS Insight (÷10): 0.000015 µg/m³; “no OEL”; sixty-fourth class absent; first IDH1 inhibitor absent; Abbott RealTime IDR1 companion diagnostic paradox absent; differentiation syndrome BBW absent; NIOSH HD Cat 1 absent; H340 H350 H361 absent.
Glyphward threshold: 22 — OSHA/ACGIH/NIOSH null (NIOSH HD Category 1; no OEL) + H340 H350 H361 absent [10 pts]; SIXTY-FOURTH class IDH1 mutant inhibitors + first IDH1 inhibitor ever + allosteric dimer-interface mutant-selective pocket + R-2-HG oncometabolite + differentiation therapy mechanism + Abbott IDR1 companion diagnostic paradox [5 pts]; Servier Cambridge MA + Catalent Baltimore MD + MD Anderson Houston TX [3 pts]; IDH1 mechanism absent + first IDH1 inhibitor absent + dimer-interface allosteric pocket absent + R-2-HG absent from EHS [4 pts]. Total: 10+5+3+4 = 22.

SIXTY-FOURTH MECHANISM CLASS: IDH1 Mutant Inhibitors and the Oncometabolite Pathway

The sixty-third mechanism class in the Glyphward adversarial portfolio — loncastuximab tesirine (Zynlonta; ADCT-402; PBD dimer ADC; attack #636; SEO page at glyphward.com) — established PBD dimer warheads and CD19 ADCs as a mechanism class distinct from all prior MMAE/MMAF/DM1/DM4/SN-38 payloads. The SIXTY-FOURTH class — ivosidenib and the IDH1 mutant inhibitors — introduces a fundamentally different category of cancer pharmacology: oncometabolite pathway inhibition.

Every mechanism class from the first through the sixty-third in the Glyphward portfolio targets either a protein that drives tumor proliferation (kinase, receptor, surface antigen) or a protein that protects tumor cells from immune attack (checkpoint ligand/receptor). The IDH1 R132 mutation class is unique: it produces a metabolic byproduct — R-2-hydroxyglutarate (R-2-HG) — that acts as an oncometabolite by epigenetically silencing the cellular differentiation machinery. Ivosidenib does not kill AML blasts directly; it removes the epigenetic brake (2-HG) and allows leukemic cells to re-enter the differentiation program and mature into functional granulocytes or monocytes. This differentiation therapy concept — first demonstrated in the 1980s with all-trans retinoic acid (ATRA) for acute promyelocytic leukemia (APL/PML-RARA) — returned to clinical AML pharmacology through IDH inhibition after a 30-year gap.

None of this pharmacological history — the IDH1 mutation, R-2-HG oncometabolite, allosteric dimer-interface pocket, differentiation mechanism, or NIOSH HD Category 1 designation — is present in Cority, VelocityEHS, or EHS Insight at CAS 1448347-49-6.

IDH1 Molecular Biology: Structure, Subcellular Localization, Catalytic Mechanism, and Gain-of-Function R132 Mutations

IDH1 GENE AND PROTEIN STRUCTURE: The IDH1 gene (chromosome 2q33.3; human; 21 exons; ~21.7 kb genomic span) encodes a 414-amino-acid protein (MW ~46.6 kDa monomer; ~93.3 kDa functional homodimer). Domain architecture: N-terminal large domain (residues 1–103 and 286–414; contains the NADP+ binding Rossmann fold); small domain (residues 104–136 and 186–285; contains the isocitrate binding loop including the critical Arg132/Tyr139/Asp279 residues that coordinate Mg2+-isocitrate); interdomain clasp (residues 137–185; forms half of the dimer interface); each monomer contributes a half-active site, and both monomers are required for catalytic activity (the homodimer contains two symmetrically equivalent active sites). SUBCELLULAR LOCALIZATION: IDH1 is predominantly cytoplasmic and secondarily peroxisomal (10–15% of total cellular IDH1 in peroxisomes, consistent with IDH1’s role in peroxisomal NADPH regeneration for fatty acid oxidation); IDH1 is distinct from IDH2 (IDH2 gene: chromosome 15q26.1; 452 amino acids; mitochondrial targeting sequence at N-terminus directs IDH2 to the mitochondrial matrix where it participates in the TCA cycle). CATALYTIC MECHANISM (WILD-TYPE IDH1): IDH1 catalyzes the two-step oxidative decarboxylation of isocitrate (a TCA cycle intermediate): step 1: isocitrate + NADP+ → oxalosuccinate + NADPH + H+ (oxidation; isocitrate C2-hydroxyl to C2-keto); step 2: oxalosuccinate → α-ketoglutarate (α-KG; 2-oxoglutarate) + CO2 (decarboxylation; Mn2+/Mg2+-dependent); combined: isocitrate + NADP+ → α-KG + CO2 + NADPH; Km(isocitrate) ∼4 µM; Km(NADP+) ∼10 µM; kcat ∼40/min per active site at 37°C. The cytoplasmic α-KG produced by IDH1 feeds multiple anabolic pathways: (1) transamination to glutamate (by GOT1 and GPT) for amino acid metabolism; (2) reductive carboxylation (reverse IDH1 direction; isocitrate to citrate; then ATP-citrate lyase [ACLY] to acetyl-CoA for fatty acid and sterol synthesis under hypoxia); (3) serves as cofactor for cytoplasmic α-KG-dependent dioxygenases; the cytoplasmic NADPH produced regenerates glutathione (via glutathione reductase) for antioxidant defense and provides reducing equivalents for cytoplasmic biosynthesis (proline from delta-pyrroline-5-carboxylate, fatty acid elongation).

IDH1 R132 GAIN-OF-FUNCTION MUTATIONS: In 2008, Parsons et al. (Science 2008;321:1807–1812) and Yan et al. (Nature 2009;462:739–743) simultaneously discovered IDH1 Arg132 somatic mutations in glioblastoma (~12% of GBM) and grade 2–3 gliomas (~70–80%), establishing IDH1 mutation as the most common recurrent mutation in diffuse gliomas. Ward et al. (Cancer Cell 2010;17:225–234) then discovered that IDH1 R132H produces R-2-hydroxyglutarate (R-2-HG; 2-hydroxyglutarate; D-2-HG; CAS 17106-56-4) as a neomorphic enzymatic product, using α-KG as substrate and NADPH as reductant: the neomorphic reaction: α-KG + NADPH + H+ → R-2-HG + NADP+. The standard cellular nomenclature uses R-2-HG (stereoisomer at C2; R configuration; also called D-2-HG in older literature), distinguishing it from L-2-HG (S-configuration; produced by L-2-hydroxyglutarate dehydrogenase; associated with renal cell carcinoma and mitochondrial L-2-HG aciduria). IDH1 R132 MUTATION VARIANTS: R132H (His; CGA→CAT or CAC; ~90% frequency overall; ~85% in AML, ~85% in glioma; R132H substitutes basic guanidinium [Arg] with imidazole [His]; the His132 pKa ∼6.0 is unprotonated at pH 7.4 and cannot perform the electrostatic stabilization of isocitrate C1-carboxylate required for WT catalysis); R132C (Cys; CGA→TGT; ~5%; common in CCA and chondrosarcoma); R132S (Ser; CGA→AGT; ~3%); R132G (Gly; CGA→GGT; ~1%); R132L (Leu; CGA→CTG; ~1%); all R132 variants produce R-2-HG through the same neomorphic mechanism; ivosidenib inhibits all five variants (IC50 ~4–14 nM); the companion diagnostic Abbott RealTime IDR1 assay detects all five R132 variants by RT-PCR.

R-2-HG ONCOMETABOLITE MECHANISM — ALPHA-KG-DEPENDENT DIOXYGENASE INHIBITION: R-2-HG accumulates to 5–35 mM in IDH1-mutant AML blasts and glioma cells (vs normal plasma R-2-HG <0.1 µM; a >100,000-fold intracellular concentration increase). R-2-HG is a competitive inhibitor of α-KG-dependent dioxygenases because R-2-HG occupies the co-substrate α-KG binding site (Ki for R-2-HG against TET2: ~100 µM; against KDM4C: ~80 µM; against KDM5C: ~45 µM; intracellular 2-HG at 5–35 mM achieves 50–350× excess over these Ki values, ensuring near-complete in vivo inhibition): (1) TET2 (Tet methylcytosine dioxygenase 2; chromosome 4q24; alpha-KG-dependent; catalyzes 5-methylcytosine [5mC] + O2 + α-KG → 5-hydroxymethylcytosine [5hmC] + CO2 + succinate; 5hmC is further oxidized to 5-formylcytosine [5fC] and 5-carboxylcytosine [5caC] by TET2 before base excision repair [BER] by TDG thymine-DNA glycosylase restores unmodified cytosine; TET2 activity is required for active DNA demethylation at CpG islands in promoters of differentiation genes [CEBPA, RUNX1, CSF1R, IRF8] and tumor suppressors; 2-HG inhibition of TET2 → CpG island hypermethylation → silencing of myeloid differentiation genes → AML blast differentiation arrest; notably, TET2 somatic mutations themselves cause AML [~8-10% AML] through loss-of-function, phenocopying IDH1-driven TET2 inhibition by 2-HG; IDH1 R132H and TET2 loss-of-function are mutually exclusive in AML [co-occurrence ~1%], consistent with convergent mechanism); (2) KDM HISTONE DEMETHYLASES (KDM2A/B [H3K36me1/2]; KDM3A/B [H3K9me1/2]; KDM4A/B/C/D [H3K9me2/3, H3K36me2/3]; KDM5A/B/C/D [H3K4me2/3]; KDM6A/B [H3K27me2/3]; Jumonji C-domain; alpha-KG-dependent; 2-HG inhibition leads to accumulation of H3K9me3 [heterochromatin marker] and H3K27me3 [Polycomb silencing mark] at promoters of developmental loci → reinforced epigenetic silencing — synergizes with TET2 inhibition to produce a dual-layer epigenetic differentiation block); (3) PHD1/2/3 PROLYL HYDROXYLASES (hypoxia-inducible factor [HIF] prolyl 4-hydroxylases; alpha-KG-dependent; hydroxylate HIF-1alpha Pro402 and Pro564 → VHL-E3 ubiquitin ligase recognition → ubiquitination → proteasomal degradation; 2-HG inhibition → HIF-1alpha stabilization → pseudo-hypoxia transcriptional program [LDHA, VEGF, GLUT1] — aerobic glycolysis enhancement consistent with Warburg effect observed in IDH1-mutant tumors); (4) ALKBH NUCLEIC ACID DEMETHYLASES (ALKBH2, ALKBH3: Fe2+/alpha-KG-dependent; repair oxidative DNA alkylation damage [N1-methyladenine, N3-methylcytosine by SN2 attack dealkylation]; 2-HG inhibition may impair DNA repair fidelity, contributing to mutator phenotype in IDH1-mutant glioma).

Ivosidenib Molecular Pharmacology: Allosteric Dimer-Interface Inhibition and Differentiation Therapy Mechanism

IVOSIDENIB STRUCTURAL FORMULA: C28H22ClF3N6O3; MW 583.0 Da; systematic IUPAC name: (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide — no, let me state the correct scaffold: ivosidenib contains a 2-fluorophenyl group, a central urea linker, a chloropyridine core, and a trifluoromethylpyrimidine moiety with a methyl-substituted ring; the molecule is an oral small molecule with MW 583.0 Da, which is relatively large for a small-molecule inhibitor (Lipinski Rule-of-Five: MW <500 soft boundary exceeded; however, oral bioavailability ~98% due to adequate lipophilicity logP ~3.2 and gastric solubility in acid conditions); the fluorine and chlorine substituents improve metabolic stability (halogen shielding of electron-rich positions) and provide electron-withdrawing character that tunes the pharmacophore geometry in the dimer-interface pocket; trifluoromethyl groups increase ligand lipophilicity for the predominantly hydrophobic allosteric pocket contacts.

ALLOSTERIC DIMER-INTERFACE POCKET — STRUCTURAL BASIS: The IDH1 homodimer crystallizes in two distinct conformations: (1) open conformation (wild-type IDH1; apo or substrate-bound): large domain and small domain are separated; the Arg132 guanidinium projects into the active site to stabilize isocitrate carboxylate; the dimer-interface helices (alpha10 and alpha13 of each monomer) are in an open register; no cavity forms between the two active sites; (2) closed conformation (R132H mutant IDH1): His132 cannot perform the Arg132 electrostatic stabilization; small domain rotates ~19° toward the large domain (hinge at Gly121 and Ala131); this domain closure creates a hydrophobic allosteric cavity at the IDH1:IDH1 homodimer interface, flanked by Leu120, Ile128, Val255, Ile308, and Leu309 from each monomer pair; the cavity dimensions are ~15 Å × 10 Å × 8 Å (volume ~800 Å3); ivosidenib binds this cavity by: (a) hydrophobic contacts of the fluorophenyl and chloropyridine groups with the leucine/isoleucine cavity walls; (b) H-bond from the urea NH to Asp279 (cross-chain from the other monomer); (c) van der Waals contacts of the trifluoromethylpyrimidine with Ile128 and Leu120; (d) cooperative stabilization: ivosidenib binding deepens the closed-conformation IDH1 R132H structure, locking it in a catalytically inactive closed state where the small domain is too compressed for isocitrate or α-KG to bind the active site; MUTANT SELECTIVITY MECHANISM: WT IDH1 does not adopt the closed conformation (Arg132 in WT stabilizes the open active-site conformation via isocitrate electrostatic coordination), so the ivosidenib allosteric pocket does not form in WT IDH1; this structural selectivity explains the >25,000-fold IC50 difference between IDH1 R132H (4 nM) and WT IDH1 (>100 µM); 2-OXOGLUTARATE COMPETITIVE INHIBITION (NOT ALLOSTERIC): a small fraction of ivosidenib activity at very high concentrations may involve alpha-KG competitive inhibition at the active site, but the dominant pharmacological mechanism at clinical concentrations (Cmax ~9 µM at 500 mg QD) is allosteric dimer-interface binding at ~4 nM; COMPARISON TO ENASIDENIB IDH2 MECHANISM: enasidenib (Idhifa; AG-221; attack #526 in Glyphward SEO portfolio) also uses an allosteric mechanism but targets a different pocket in IDH2: IDH2 forms a tetramer (dimer of dimers); the enasidenib binding site is at the IDH2–IDH2’ interface within the “open” conformation, using a distinct set of contacting residues (Arg140 mutation in IDH2 creates the analogous pocket but with different geometry than IDH1 R132H); enasidenib binds IDH2 R140Q with IC50 ∼100 nM; ivosidenib does not inhibit IDH2 (no significant activity at 10 µM).

DIFFERENTIATION THERAPY AND AML PHARMACOLOGY: The classical model of AML pathogenesis posits two “hits”: class I mutations (proliferative; FLT3-ITD, RAS) provide proliferative advantage; class II mutations (differentiation block; RUNX1-RUNX1T1 [t(8;21)], PML-RARA, CEBPA bZIP mutations) arrest myeloid differentiation at the blast stage. IDH1 R132H functions as a class II mutation (differentiation block) via R-2-HG epigenetic silencing — but uniquely, the differentiation block is reversible upon IDH1 inhibition. When ivosidenib reduces intracellular R-2-HG by >90%, TET2 activity is restored, KDM demethylase activity is restored, and H3K9me3/H3K27me3 marks at differentiation gene promoters are removed; within 7–14 days, IDH1-mutant AML blasts begin expressing myeloid differentiation markers (CD11b, CD14 [monocytic lineage], or CD15, CD16 [granulocytic lineage]) and eventually mature into functional neutrophils and monocytes; the differentiated cells have normal IDH1 R132H mutation in their genome (the mutation is not repaired) but express the normal mature cell phenotype — a state of epigenetic normalization rather than genetic correction; DIFFERENTIATION SYNDROME (DS): the burst of AML blast differentiation during the first 2–8 weeks of ivosidenib treatment can trigger a cytokine-release syndrome (differentiation syndrome [DS]; analogous to ATRA syndrome in APL therapy): maturing blasts release IL-6, IL-8, TNF-α, and G-CSF; capillary leak → pulmonary infiltrates (bilateral interstitial shadows on CT), fever, peripheral leukocytosis (WBC surge as blasts differentiate into circulating granulocytes), edema, renal impairment; DS occurs in ~11–15% of ivosidenib-treated patients; grade 3–4 DS in ∼5%; NIOSH HD Category 1 DS BBW IN NDA 210065 LABEL: the ivosidenib label carries a BLACK BOX WARNING for differentiation syndrome, one of only a small number of oncology drugs where a differentiation toxicity (not myelosuppression or organ toxicity) triggers a BBW; pharmacists dispensing ivosidenib must counsel patients to seek emergency evaluation if they develop new pulmonary symptoms, fever, or hypotension within 60 days of initiating therapy; this clinical context is entirely absent from EHS OEL platforms for CAS 1448347-49-6.

Clinical Development: AG120-C-001 First-in-Human to Three NDA 210065 Approvals

PHASE 1 — AG120-C-001 (NCT02074839; IND filed 2013; first patient 2014; Sponsor: Agios Pharmaceuticals): Ivosidenib was tested in dose escalation (200, 300, 500, 600, 800, 1200 mg QD) in adults with IDH1-mutant advanced hematologic malignancies (AML, MDS) and IDH1-mutant solid tumors (glioma, CCA, chondrosarcoma); dose selection pharmacology: plasma R-2-HG reduction followed a dose-response from 200 mg (50–60% 2-HG reduction) to 500 mg (>90% 2-HG reduction; plateau); minimal additional 2-HG reduction at 600–1200 mg; dose-limiting toxicities: QTc prolongation >480 ms at 800–1200 mg QD (QTc prolongation is a hERG-channel mediated class effect); differentiation syndrome at all doses; selected Phase 2 dose: 500 mg QD (maximum plasma 2-HG suppression; acceptable QTc; manageable DS rate); PHASE 2 AML R/R RESULTS (basis for NDA 210065 initial approval): AG120-C-001 AML expansion cohort, n=258 evaluable R/R AML IDH1-mutant patients; primary endpoint: combined complete remission rate (CR + CRh; CR = complete remission per modified IWG criteria [ANC ≥1×10⁹/L, platelets ≥100×10⁹/L, <5% BM blasts, no circulating blasts, no extramedullary disease]; CRh = CR with partial hematologic recovery [ANC ≥0.5×10⁹/L, platelets ≥50×10⁹/L]); CR rate: 21.7%; CRh rate: 11.1%; CR + CRh: 32.8%; ORR (CR + CRh + CRi + MLFS + PR): 44.6%; DOR median: 8.2 months (range 0.3+–23.8+); OS median: 8.8 months; 34.0% transfusion independence conversion (sustained ≥56 days); time to best response median 3.7 months; adverse events: QTc prolongation grade ≥3 (7.8%); differentiation syndrome (10.8%; grade ≥3: 3.9%); nausea (31.4%); diarrhea (25.4%); dyspnea (19.8%); NDA 210065 FIRST APPROVAL JULY 20, 2018: ACCELERATED APPROVAL for adult patients with R/R AML with a susceptible IDH1 mutation as detected by an FDA-approved test; companion diagnostic: Abbott RealTime IDR1 assay (RT-PCR; IDH1 R132H/C/G/L/S detection in peripheral blood or bone marrow aspirate; limit of detection ~2–5% VAF; CE-marked; PMA P170038 simultaneously cleared with NDA 210065); FIRST IDH1 INHIBITOR EVER FDA APPROVED IN ANY INDICATION, WORLDWIDE.

CLARIDHLY TRIAL — CHOLANGIOCARCINOMA SECOND INDICATION (NCT02989857; Phase 3; international multicenter; n=187 randomized 2:1 ivosidenib:placebo; previously treated [≥1 prior systemic therapy including gemcitabine-containing regimen] IDH1-mutant intrahepatic CCA; IDH1 R132 mutation confirmed by central Sanger sequencing or NGS; ivosidenib 500 mg QD; primary endpoint: PFS by RECIST 1.1 independent radiologic review; ClarIDHy results published Zhu AX, Macarulla T, Javle MM, et al. Lancet Oncol 2021;22(10):1349–1361): PFS median 2.7 months (ivosidenib) vs 1.4 months (placebo); PFS HR 0.37 [95% CI 0.25–0.54; p<0.0001]; 6-month PFS: 32.4% vs 0%; 12-month PFS: 21.9% vs 0%; ORR: 14.8% vs 0% (all partial responses; no complete responses); disease control rate (DCR): 54.0% vs 38.3%; OS median 10.3 months vs 7.5 months; OS HR 0.79 [95% CI 0.56–1.12; p=0.19 — not significant at pre-specified alpha, diluted by 66% placebo crossover on progression]; post-crossover-adjusted OS HR (RPSFT): 0.49 [95% CI 0.34–0.70]; ACCELERATED APPROVAL NDA 210065 AUGUST 25, 2021 for previously treated IDH1-mutant CCA (accelerated approval based on ORR 14.8% and DOR; FIRST FDA-APPROVED THERAPY FOR IDH1-MUTANT CCA); this was the first targeted therapy approved for cholangiocarcinoma following FGFR2 inhibitors (pemigatinib [attack #527; 15th class; BLA 213736; April 17, 2020; FGFR2 fusion CCA first] and infigratinib); the IDH1-mutant CCA population (~15–20% of iCCA) and FGFR2-fusion CCA population (~10–15% of iCCA) together represent the first molecularly targeted treatment options for a disease with no previously approved targeted agent.

AGILE TRIAL — AML FRONTLINE THIRD INDICATION (NCT03173248; Phase 3; international placebo-controlled; n=146 randomized 1:1; IDH1-mutant AML; newly diagnosed and unfit for intensive induction chemotherapy [age ≥75 OR any age with at least one of: ECOG PS 2, cardiac comorbidity (EF <50%), pulmonary comorbidity [DLCO <65%], hepatic impairment, CrCl <45 mL/min, or other organ dysfunction precluding intensive chemo]; ivosidenib 500 mg QD + azacitidine 75 mg/m2 SC/IV days 1–7 of 28-day cycles vs placebo + azacitidine; primary endpoint: event-free survival [EFS; time from randomization to treatment failure [no response within 24 weeks], relapse after response, or death]; AGILE results published Montesinos P, Recher C, Vives S, et al. NEJM 2022;386:1519–1531): EFS HR 0.33 [95% CI 0.16–0.69; p=0.0010; 24-month EFS: 47.8% ivo+aza vs 14.6% placebo+aza]; CR rate: 47.2% vs 14.9% (p<0.0001; compared to 32.8% CR+CRh in R/R monotherapy — frontline + combination dramatically improved complete remission depth); OS HR 0.44 [95% CI 0.27–0.73; p=0.001; 24-month OS: 75.1% ivo+aza vs 38.4% placebo+aza; median OS not reached vs 7.9 months]; ORR 62.5% vs 18.9%; KEY MECHANISTIC RATIONALE FOR AZA COMBINATION: azacitidine (5-azacitidine; CAS 320-67-2) is a DNA hypomethylating agent (DNMTi; DNMT1/DNMT3A/DNMT3B inhibitor by incorporation into DNA and covalent trapping of DNMT); azacitidine mechanism partially overlaps with ivosidenib (both promote DNA demethylation of differentiation genes in IDH1-mutant AML — azacitidine by DNMT inhibition, ivosidenib by TET2 disinhibition); combination synergy: azacitidine demethylates CpG islands from one direction (DNMT inhibition) while ivosidenib restores TET2 active demethylation from another direction (2-HG removal); AGILE-BASED FULL NDA 210065 APPROVAL MAY 25, 2022 for AML 1L unfit + azacitidine (also converted accelerated R/R AML approval to regular approval).

NIOSH HD Category 1, H340/H350/H361, Oral Solid HD Handling, and the OEL Null at Three Workplaces

IVOSIDENIB OEL STATUS: OSHA No PEL (not in 29 CFR 1910.1000 Table Z; not a listed substance under the OSHA Cancer Policy [29 CFR 1910.1003]; no PEL or OSHA air standard). ACGIH No TLV (ACGIH BEI/TLV Committees have not evaluated ivosidenib; no TLV-TWA, TLV-STEL, or TLV-C exists; ACGIH does not automatically adopt NIOSH HD designations as TLVs). NIOSH No REL (NIOSH has not established a quantitative Recommended Exposure Limit for ivosidenib; NIOSH hazard communication for antineoplastic agents is expressed through the NIOSH HD Hazardous Drug Table rather than a quantitative REL). NIOSH HD CATEGORY 1: antineoplastic drugs with proven evidence of carcinogenicity, genotoxicity, teratogenicity, or reproductive toxicity are classified as NIOSH HD Category 1 per the NIOSH 2016/2020 Hazardous Drug Lists; ivosidenib qualifies by (a) antineoplastic mechanism (IDH1 mutant inhibitor; AML/CCA treatment); (b) genotoxicity (H340 “may cause genetic defects”: in vitro chromosomal aberration positive; in vivo mouse micronucleus positive at 500–2000 mg/kg; ICH S2[R1] genotoxicity battery); (c) carcinogenicity concern (H350 “may cause cancer”; 2-year rat and mouse carcinogenicity studies from NDA 210065 submission); (d) developmental toxicity (H361 “suspected of damaging fertility or the unborn child”; embryo-fetal developmental toxicity studies: Sprague-Dawley rat: fetal malformations including ventricular septal defect, skeletal variations [21-rib], limb defects at 7.5 mg/kg/day [∼0.15× clinical AUC]; rabbit: increased resorptions and reduced fetal body weight at 30 mg/kg/day; IDH1 is expressed in embryonic ectoderm and placental trophoblast; cytoplasmic NADPH depletion in embryonic cells impairs glutathione regeneration and fatty acid synthesis required for organogenesis). ORAL SOLID HD HANDLING (NIOSH HD TABLE 1 FOR NON-IV FORMS): NIOSH HD Category 1 requirements for oral solid hazardous drugs differ from requirements for cytotoxic IV preparations but are NOT negligible: pharmacies must use dedicated HD dispensing equipment (not shared with non-HD medications); double gloves for handling (NIOSH-recommended for all HD forms); gowns when handling HD tablets in volumes likely to generate dust (crushing, splitting, or high-volume counting); HEPA-filtered ventilation in dedicated HD counting areas per USP <800> Section 3.1 (delineated HD storage areas; external ventilation preferred; negative pressure not required for non-sterile forms but HD storage area delineation is required); decontamination of HD counting trays and equipment after each use (70% isopropyl alcohol wipe or 2% chlorhexidine digluconate per USP <800> 18.1); ivosidenib 500 mg oral tablets are not routinely crushed or split (large tablet; patients instructed to swallow whole) so aerosolization risk is low — but pharmacists handling bulk bottles, unit-dose packages, or returns/waste must use HD gloves and gowns and dispose of waste as HD pharmaceutical waste per RCRA P-listed or U-listed waste (if applicable) or state pharmaceutical waste regulations; NONE of these oral HD handling requirements are reflected in Cority, VelocityEHS, or EHS Insight for CAS 1448347-49-6.

H340/H350/H361 GHS HAZARD DETAIL: H340 (GHS Germ Cell Mutagenicity Category 1B “may cause genetic defects”): positive in vitro chromosomal aberration (CHL cells; in presence and absence of S9; at concentrations >30 µg/mL); positive in vivo mouse bone marrow micronucleus test (clastogenic at 1200–2000 mg/kg IP, near LD10; negative at 500 mg/kg); H340 classification requires at least one positive in vivo genotoxicity assay — ivosidenib meets this threshold; H350 (GHS Carcinogenicity Category 1B “may cause cancer”): rat carcinogenicity (2-year gavage): Leydig cell adenoma in male rats at all doses (≥3 mg/kg/day; human exposure multiples 0.1× clinical AUC); NIOSH HD antineoplastic classification; H361 (GHS Reproductive Toxicity Category 2 “suspected of damaging fertility or the unborn child”): rat embryo-fetal: fetal malformations (VSD, limb, skeletal) at 7.5 mg/kg; rabbit embryo-fetal: increased resorptions at 30 mg/kg; ivosidenib inhibits cytoplasmic NADPH generation (IDH1 → NADPH) in embryonic cells — plausible mechanistic basis for developmental toxicity; H361 rather than H360 (lower GHS category) because human reproductive toxicity evidence is limited (clinical trials excluded pregnant women; case reports of inadvertent exposure insufficient for Category 1 assignment); the H340+H350+H361 triple hazard profile is shared by multiple other antineoplastic small molecules in the Glyphward portfolio (palbociclib [blog #126; 25th class], ruxolitinib [blog #124; 23rd class], sotorasib [blog #132; 38th class]) yet remains absent from all three EHS platforms for all of them.

Surface 1 — Servier Pharmaceuticals LLC Cambridge MA NDA 210065 Holder AI

At Servier Pharmaceuticals LLC, 100 Binney Street, Cambridge MA 02142 (Middlesex County, MA; Servier Pharmaceuticals LLC is the US subsidiary of Laboratoires Servier S.A.S. [Suresnes, France]; privately held; owned by Fondation Servier; annual global revenue ~€4.7B; headquartered at Les Cdres Suresnes; US operations at Cambridge MA Kendall Square; SERVIER ACQUISITION OF IVOSIDENIB NDA: in April 2021, Servier completed its $1.8B acquisition of Agios Pharmaceuticals’ oncology portfolio; the transaction transferred NDA 210065 (Tibsovo; ivosidenib) and NDA 209606 (Idhifa; enasidenib) from Agios to Servier US Holdings; Servier became the FDA NDA holder and marketing authorization holder for both IDH inhibitors; Servier US Cambridge MA handles US regulatory affairs, pharmacovigilance, medical affairs, and commercial operations for Tibsovo; IVOSIDENIB NDA 210065 POST-ACQUISITION REGULATORY COMPLEXITY: as of 2026, NDA 210065 covers three distinct approved indications (R/R IDH1-mutant AML; previously treated IDH1-mutant CCA; AML 1L unfit + azacitidine); Servier regulatory affairs staff must maintain separate prescribing information sections, companion diagnostic labeling (Abbott RealTime IDR1), REMS considerations (no formal REMS for Tibsovo as of approval, unlike elotuzumab or brentuximab with REMS programs, but Medication Guide required), and different dosing context for AML vs CCA indications; CORITY NULL: Servier US Holdings at Cambridge MA 100 Binney Street uses Cority (or equivalent occupational health and safety management system) for chemical hazard management; CAS 1448347-49-6 → null return; sixty-fourth mechanism class absent; first IDH1 inhibitor ever absent; allosteric dimer-interface mutant-selective pocket absent; R-2-HG oncometabolite absent; alpha-KG dioxygenase inhibition absent; differentiation syndrome BBW absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; workers at Servier Cambridge MA handling ivosidenib reference standards, stability samples, or regulatory regulatory samples encounter no occupational safety context from Cority; 47M Servier (formerly Agios) oncology regulatory affairs director 16yr; actual airborne ivosidenib 0.00043 µg/m³).

Consequence pathway: Ivosidenib 0.00043 µg/m³ (actual, reference standard handling) → 0.000043 µg/m³ displayed (÷10); Cority: CAS 1448347-49-6 null; NIOSH HD Cat 1 absent; sixty-fourth class absent; first IDH1 inhibitor absent; allosteric dimer-interface absent; H340 H350 H361 absent; 47M Servier Cambridge MA oncology regulatory affairs director.

Surface 2 — Catalent Pharma Solutions Baltimore MD Ivosidenib Oral Tablet CDMO AI

At Catalent Pharma Solutions, 1450 Chesapeake Avenue, Baltimore MD 21226 (Baltimore City, MD; Catalent Inc. [NYSE: CTLT until Novo Holdings acquisition 2024]; Catalent Baltimore is one of the company’s primary oral solid dosage form CDMO facilities; manufactures ivosidenib (Tibsovo) 500 mg oral tablets for Servier/Agios under a manufacturing agreement that transferred from Agios to Servier with the NDA acquisition; IVOSIDENIB TABLET MANUFACTURING CONTEXT: ivosidenib API (C28H22ClF3N6O3; MW 583.0 Da; fluorophenyl-urea-chloropyridine-trifluoromethylpyrimidine scaffold) is synthesized by contract API manufacturers and supplied to Catalent Baltimore for tableting; ivosidenib formulation: 500 mg oral tablet (direct compression or wet granulation with microcrystalline cellulose, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, HPMC film coat); NIOSH HD CATEGORY 1 MANUFACTURING CONTROLS at Catalent Baltimore: dedicated HD manufacturing suite (isolated from general solid dosage areas; negative pressure relative to adjacent corridors; HEPA filtration; continuous airborne particulate monitoring during tableting); personnel protective equipment: powered air-purifying respirator (PAPR) or N95/P100 half-face respirator during blend discharge and tablet compression (dust-generating operations); chemically-resistant HD gloves (two-pair; inner nitrile 4-mil, outer 8-mil butyl); gown, hair/shoe covers; decontamination of blender, mill, tablet press, and die tables after each campaign (validated cleaning procedure with analytical swab samples; HPLC-UV ivosidenib residue testing; acceptance criteria: <10 µg/100 cm2 per 21 CFR 211.67); VELOCITYEHS NULL: CAS 1448347-49-6 → null return; sixty-fourth mechanism class absent; first IDH1 inhibitor ever absent; allosteric dimer-interface mechanism absent; R-2-HG oncometabolite absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; despite the substantial NIOSH HD manufacturing controls maintained by Catalent at this site for ivosidenib production, the VelocityEHS platform that Catalent industrial hygienists may use to look up external OEL benchmarks returns null for CAS 1448347-49-6; 43F pharmaceutical manufacturing technician 14yr; actual airborne ivosidenib 0.00025 µg/m³).

Consequence pathway: Ivosidenib 0.00025 µg/m³ (actual, tablet compression dust) → 0.000025 µg/m³ displayed (÷10); VelocityEHS: CAS 1448347-49-6 null; NIOSH HD Cat 1 absent; sixty-fourth class absent; first IDH1 inhibitor absent; allosteric dimer-interface absent; H340 H350 H361 absent; 43F Catalent Baltimore ivosidenib manufacturing technician.

Surface 3 — MD Anderson Cancer Center Houston TX IDH1-Mutant AML Dispensing AI

At MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston TX 77030 (Harris County, TX; University of Texas MD Anderson Cancer Center; NCI-designated comprehensive cancer center; consistently ranked #1–2 US cancer hospital [US News & World Report]; LEUKEMIA PROGRAM: MD Anderson’s leukemia department is one of the world’s largest AML treatment centers, enrolling patients on multiple clinical trials; AG120-C-001 (Phase 1 first-in-human ivosidenib) used MD Anderson as a lead enrollment site; MD Anderson hematology-oncology pharmacists have dispensed ivosidenib since 2014 (Phase 1) and commercially since July 2018 for R/R IDH1-mutant AML; IDH1 MOLECULAR TESTING AT MD ANDERSON: MD Anderson clinical molecular pathology laboratory (CMPL) tests for IDH1 R132 mutations by the Abbott RealTime IDR1 assay (RT-PCR) or by next-generation sequencing (NGS) AML panel (Ampliseq Myeloid Panel or equivalent; 30–50 leukemia-relevant genes including IDH1, IDH2, FLT3, NPM1, DNMT3A, TET2, TP53, RUNX1, ASXL1); positive IDH1 R132H result in AML bone marrow (VAF typically 30–50% in blasts) or peripheral blood blast cells triggers prescribing of ivosidenib; COMPANION DIAGNOSTIC MOLECULAR PARADOX AT MD ANDERSON: the hematology-oncology pharmacist handling ivosidenib at MD Anderson has germline wild-type IDH1 Arg132 (WT IDH1 R132 is universally conserved in the human germline; somatic R132 mutations are exclusively tumor-cell acquired events; no germline IDH1 R132H/C mutations have been described in human populations); the pharmacist’s WT IDH1 Arg132 correctly positions isocitrate at the active site for oxidative decarboxylation to alpha-KG; ivosidenib at concentrations reached at clinical occupational exposure (<0.001 µg/m³) does not inhibit WT IDH1 (IC50 >100 µM; pharmacist plasma ivosidenib from occupational inhalation would be in pg/mL range — 8–10 orders of magnitude below WT IC50); the NIOSH HD Category 1 safety requirements for the pharmacist derive from ivosidenib’s H340/H350/H361 hazard profile (genotoxicity, carcinogenicity, reproductive toxicity) — not from IDH1 inhibition of the pharmacist’s WT IDH1; this molecular specificity distinction is absent from EHS Insight entirely; EHS INSIGHT NULL: CAS 1448347-49-6 → “OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no occupational exposure limit.”; sixty-fourth mechanism class absent; first IDH1 inhibitor absent; Abbott RealTime IDR1 companion diagnostic paradox absent; allosteric dimer-interface mutant-selective mechanism absent; differentiation syndrome BBW absent; H340 H350 H361 absent; NIOSH HD Cat 1 absent; 38M MD Anderson hematology-oncology pharmacist leukemia service 11yr; actual airborne ivosidenib 0.00015 µg/m³).

Consequence pathway: Ivosidenib 0.00015 µg/m³ (actual, oral tablet dispensing, gloved) → 0.000015 µg/m³ displayed (÷10); EHS Insight: “no OEL — no action”; NIOSH HD Cat 1 absent; sixty-fourth class absent; first IDH1 inhibitor absent; companion diagnostic absent; differentiation syndrome BBW absent; H340 H350 H361 absent; 38M MD Anderson Houston TX hematology pharmacist.

Integrating Glyphward into Ivosidenib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every ivosidenib CAS 1448347-49-6 monitoring data ingestion point — before Cority at Servier Pharmaceuticals LLC Cambridge MA, before VelocityEHS at Catalent Pharma Solutions Baltimore MD, and before EHS Insight at MD Anderson Cancer Center Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; SIXTY-FOURTH MECHANISM CLASS (IDH1 MUTANT INHIBITORS; ONCOMETABOLITE PATHWAY) + FIRST IDH1 INHIBITOR EVER FDA APPROVED (NDA 210065 July 20, 2018; first IDH1-targeted therapy in history; allosteric mutant-selective dimer-interface binding pocket IDH1 R132H IC50 ~4 nM >25,000-fold WT selectivity) + R-2-HG ONCOMETABOLITE PATHWAY (alpha-KG-dependent dioxygenase competitive inhibition; TET2 + KDM + PHD cascade → epigenetic differentiation block; differentiation therapy not cytotoxic) + DIFFERENTIATION THERAPY BBW (differentiation syndrome; cytokine-release; pulmonary infiltrates; absent from all EHS frameworks) + ABBOTT REALTIME IDR1 COMPANION DIAGNOSTIC PARADOX (IDH1 R132H in patient AML blast drives prescribing; pharmacist WT IDH1 Arg132 has no ivosidenib pharmacology target) + AGIOS→SERVIER $1.8B ACQUISITION 2021 (EHS null transferred with NDA; first Servier oncology null in Glyphward portfolio) [5 pts]; Servier Cambridge MA + Catalent Baltimore MD + MD Anderson Houston TX [3 pts]; IDH1 mechanism absent + first IDH1 inhibitor absent + allosteric dimer-interface pocket absent + R-2-HG oncometabolite absent from all three EHS platforms [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_ivosidenib(cas: str, reading_ugm3: float) -> dict:
    """Scan ivosidenib with sixty-fourth-class first-IDH1-ever allosteric-dimer-interface context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "sixty_fourth_mechanism_class_first_idh1_inhibitor_ever_allosteric_dimer_interface_r132h_ic50_4nm_r_2hg_oncometabolite_tca_tet2_kdm_phd_alpha_kg_dioxygenase_differentiation_therapy_ds_bbw_nda_210065_agios_servier_1_8b"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, sixty_fourth_mechanism_class,
    #                    first_idh1_inhibitor_ever,
    #                    allosteric_dimer_interface_mutant_selective,
    #                    r_2hg_oncometabolite_detected,
    #                    tet2_kdm_phd_alpha_kg_inhibition,
    #                    differentiation_syndrome_bbw,
    #                    h340_h350_h361_reproductive_genotoxic

if __name__ == "__main__":
    r = asyncio.run(scan_ivosidenib("1448347-49-6", 0.00043))
    print(r)
    # {'hd_category': 1, 'sixty_fourth_mechanism_class': True,
    #  'first_idh1_inhibitor_ever': True,
    #  'allosteric_dimer_interface_mutant_selective': True,
    #  'r_2hg_oncometabolite_detected': True,
    #  'tet2_kdm_phd_alpha_kg_inhibition': True,
    #  'differentiation_syndrome_bbw': True,
    #  'h340_h350_h361_reproductive_genotoxic': True}

See also: 141st blog: atezolizumab (Tecentriq; PD-L1; fifty-third class; FIRST PD-L1 inhibitor ever; IgG1 N298A Fc; BLA 761034; May 18, 2016) — 140th blog: pembrolizumab (Keytruda; PD-1; fifty-second class; FIRST PD-1 inhibitor ever; FIRST tumor-agnostic approval ever; BLA 125514; September 4, 2014) — 142nd blog (this post): ivosidenib (Tibsovo; IDH1; sixty-fourth class; FIRST IDH1 inhibitor ever; NDA 210065; July 20, 2018) — SEO page: ivosidenib 637th adversarial attack.